9,529 results match your criteria Anemia of Chronic Disease and Renal Failure

[Prevalence and risk factors of preoperative deep venous thromboembolism in spinal fracture].

Zhongguo Gu Shang 2022 Aug;35(8):717-23

Department of General Surgery, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang, China.

Objective: To investigate the incidence of lower extremity deep vein thrombosis (DVT) before surgery in patients with spinal fracture and analyze its risk factors.

Methods: The clinical data of 1 046 patients with spinal fracture who underwent surgery from October 2017 to December 2020 were retrospectively analyzed, including patient's age, gender, body mass index (BMI), smoking history, complications, the time from injury to diagnosis of DVT, blood index results on admission. The complications included hypertension, osteoporosis, diabetes, coronary heart disease, chronic obstructive pulmonary disease (COPD), anemia, obesity, hypokalemia, hyponatremia, hypoproteinemia, renal insufficiency, spinal cord injury;blood index results on admission included hematocrit (HCT), creatinine (Cre), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein(LDL), D-dimer(D-D), fibrin/fibrinogen degradation products(FDP), and C-reactive protein(CRP). Read More

View Article and Full-Text PDF

Improving Detection and Management of Anemia in CKD.

J Fam Pract 2022 Jul;71(6 Suppl):S23-S28

Stephen Brunton, MD, FAAFP, Executive Director, Primary Care Metabolic Group.

Learning Objectives: At the end of the activity, participants will be able to:Describe approaches to improve recognition of chronic kidney disease (CKD) and anemia in primary care. Explain the importance of early management of anemia in CKD to reduce adverse outcomes and improve symptoms. Prescribe evidence-based treatment for patients with anemia in CKD who can be managed in the primary care setting. Read More

View Article and Full-Text PDF

Low mean HbA1c does not increase all-cause and cardiovascular mortality in patients with diabetes: Effect-modifications by anemia and chronic kidney disease stages.

PLoS One 2022 11;17(8):e0272137. Epub 2022 Aug 11.

Department of Endocrinology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.

Background: Previous studies reported that low levels of glycated hemoglobin A1c (HbA1c) were associated with increased mortality. We investigated rates and risks of all-cause and cardiovascular mortality in association with mean HbA1c levels with stratification of anemia and chronic kidney disease (CKD) stages, major causes of low HbA1c.

Methods: 47,145 patients with prescription of antidiabetic agents >6 months in the outpatient visits (2003-2018) were linked to Taiwan's National Death Registry to identify all-cause and cardiovascular mortality. Read More

View Article and Full-Text PDF

Spontaneous Twin Pregnancy: A Challenging and Exceptional Scenario in a Patient on Maintenance Hemodialysis in Sub-Saharan Africa.

Case Rep Nephrol Dial 2022 May-Aug;12(2):90-95. Epub 2022 Jun 7.

Nephrology Service, Yaounde General Hospital, Yaounde, Cameroon.

Chronic hemodialysis is associated with reduced fertility. Hence, pregnancy remains rare, challenging, and deleterious when unplanned, especially in low-resource countries. Contraception and births are very important in these settings. Read More

View Article and Full-Text PDF

Identifying Patients at Risk for Venous Thromboembolic Events After Isolated Upper Extremity Trauma: A Predictive Scale.

Orthopedics 2022 Aug 10:1-8. Epub 2022 Aug 10.

Previous studies have defined risk factors for development of venous thromboembolisms (VTEs) among patients with lower extremity orthopedic trauma. Limited data exist on this risk after upper extremity orthopedic trauma. A total of 269,137 incidents of upper extremity orthopedic trauma (fractures of the clavicle, scapula, humerus, elbow, or lower arm) were identified in the State Inpatient Database for 4 states included in the analysis (California, Florida, New York, and Washington) from 2006 to 2014. Read More

View Article and Full-Text PDF

The KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD): A Korean Chronic Kidney Disease Cohort.

J Prev Med Public Health 2022 Jul 1;55(4):313-320. Epub 2022 Jul 1.

Department of Internal Medicine, National Medical Center, Seoul, Korea.

The KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) was launched in 2011 with the support of the Korea Disease Control and Prevention Agency. The study was designed with the aim of exploring the various clinical features and characteristics of chronic kidney disease (CKD) in Koreans, and elucidating the risk factors for CKD progression and adverse outcomes of CKD. For the cohort study, nephrologists at 9 tertiary university-affiliated hospitals participated in patient recruitment and follow-up. Read More

View Article and Full-Text PDF

Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia.

Front Cell Infect Microbiol 2022 22;12:919352. Epub 2022 Jul 22.

Department of Nephrology, Minhang Hospital, Fudan University, Shanghai, China.

The main treatment for renal anemia in end-stage renal disease (ESRD) patients on hemodialysis is erythropoiesis (EPO). EPO hyporesponsiveness (EH) in dialysis patients is a common clinical problem, which is poorly understood. Recent searches reported that gut microbiota was closely related to the occurrence and development of ESRD. Read More

View Article and Full-Text PDF

Characteristics and complications of fracture in older adults with chronic kidney disease: a cross-sectional study.

J Orthop Surg Res 2022 Aug 6;17(1):377. Epub 2022 Aug 6.

Department of Orthopaedic Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, Hebei, People's Republic of China.

Background: The aim of this study was to analyze the clinical characteristics of older fracture patients with chronic kidney disease (CKD) and to determine the risk factors of perioperative cardiovascular complications.

Methods: We retrospectively reviewed clinical data of older fracture patients with CKD admitted to the Third Hospital of Hebei Medical University from January 2016 to October 2021. The data we collected included baseline characteristics and complications. Read More

View Article and Full-Text PDF

[High patient unawareness for chronic kidney disease even in later stages - but why is it more frequent in women than in men?]

Dtsch Med Wochenschr 2022 Aug 4. Epub 2022 Aug 4.

Leibniz Universität Hannover, Institut für Technische Chemie, Hannover.

Introduction:  Chronic kidney failure (CKD) is as common as diabetes or coronary heart disease in a population aged 40 years and older. Although CKD increases the risk of secondary diseases or premature death, patients with CKD are often unaware of their disease. In a recent analysis of German data, unawareness CKD was higher in women than in men. Read More

View Article and Full-Text PDF

Levels of Lead in Residential Drinking Water and Iron Deficiency among Patients with End Stage Kidney Disease.

Kidney360 2022 07 29;3(7):1210-1216. Epub 2022 Apr 29.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Background: Although those with kidney disease may have heightened susceptibility to heavy metal toxicity, whether low levels of drinking water lead contamination have clinical consequence is unknown.

Methods: Given that lead toxicity is known to associate with iron deficiency, we merged data from the Environmental Protection Agency (EPA) Safe Drinking Water Information and United States Renal Data Systems to examine whether municipal 90th percentile drinking water lead levels associate with iron deficiency among incident dialysis patients. Iron deficiency was defined across thresholds of transferrin saturation (<10% and 20%) and ferritin (<100 and <200 ng/ml), and simultaneous transferrin saturation <20% and ferritin <200 ng/ml, all obtained within 30 days of dialysis initiation. Read More

View Article and Full-Text PDF

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.

Ren Fail 2022 Dec;44(1):1112-1122

The Second Affiliated Hospital, Hengyang Medical School, Department of Endocrinology and Metabolism, University of South China, China, Hengyang, China.

Background: Hyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemia and anemia.

Methods: Relevant literature from PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CCRCT) and MEDLINE databases were searched up to 21 February 2022, in order to conduct a meta-analysis to investigate the efficacy, safety and economic benefits of ferric citrate treatment in CKD patients with hyperphosphatemia and anemia. Read More

View Article and Full-Text PDF
December 2022

Impact of Non-cardiac Comorbidities on Long-Term Clinical Outcomes and Health Status After Acute Heart Failure in China.

Front Cardiovasc Med 2022 13;9:883737. Epub 2022 Jul 13.

National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Individual non-cardiac comorbidities are prevalent in HF; however, few studies reported how the aggregate burden of non-cardiac comorbidities affects long-term outcomes, and it is unknown whether this burden is associated with changes in health status.

Aims: To assess the association of the overall burden of non-cardiac comorbidities with clinical outcomes and quality of life (QoL) in patients hospitalized for heart failure (HF).

Methods: We prospectively enrolled patients hospitalized for HF from 52 hospitals in China. Read More

View Article and Full-Text PDF

Challenges in Management of Kidney Failure in a Free Clinic Setting: A Case Report.

Cureus 2022 Jun 26;14(6):e26352. Epub 2022 Jun 26.

Rheumatology, Dr. Gary Burnstein Community Health Clinic, Pontiac, USA.

Chronic kidney disease (CKD) is a condition that involves the deterioration of renal function over the course of months to years. Various clinical manifestations occur at the initial insult to the kidney, ranging from subtle changes in metabolic and volume control to asymptomatic hematuria, hypertension, and diabetes. The kidneys can adapt to damage or injury, but if left untreated, then there is a possibility of a gradual decline in renal function that progresses to kidney failure that requires dialysis. Read More

View Article and Full-Text PDF

The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.

BMC Nephrol 2022 07 27;23(1):268. Epub 2022 Jul 27.

King's College Hospital NHS Trust, London, UK.

Background: Many people living with chronic kidney disease (CKD) are iron deficient, even though they may not be anaemic. The Iron and Muscle study aims to evaluate whether iron supplementation reduces symptoms of fatigue, improves muscle metabolism, and leads to enhanced exercise capacity and physical function. We report here the trial design and baseline characteristics. Read More

View Article and Full-Text PDF

Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?

Curr Opin Nephrol Hypertens 2022 Sep 15;31(5):399-405. Epub 2022 Jul 15.

Department of Renal Medicine, King's College Hospital, London, UK.

Purpose Of Review: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors have recently been developed as a new treatment for anemia associated with chronic kidney disease (CKD). Several of these have been approved in Europe (roxadustat), China, and Japan, but none approved in the United States to date, although daprodustat has been submitted as a new drug application to the Food and Drug Administration. The aim of this review is to critically appraise the available data, particularly the most recent publications, and offer a personal viewpoint on whether or not these drugs are ready for primetime. Read More

View Article and Full-Text PDF
September 2022

Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review.

Clin Kidney J 2022 Aug 26;15(8):1483-1505. Epub 2022 Feb 26.

Royal Hospital for Children Glasgow, Paediatric Nephrology, Glasgow, UK.

Background: Erythropoiesis-stimulating agents (ESAs) revolutionized the management of anaemia in chronic kidney disease (CKD) when introduced in the late 1980s. A range of ESA types, preparations and administration modalities now exist, with newer agents requiring less frequent administration. Although systematic reviews and meta-analyses have been published in adults, no systematic review has been conducted investigating ESAs in children. Read More

View Article and Full-Text PDF

Successful Treatment of Refractory Anemia in a Patient With Glycogen Storage Disease Type Ia Undergoing Hemodialysis.

Cureus 2022 Jun 22;14(6):e26213. Epub 2022 Jun 22.

Nephrology, Shimane Prefectural Central Hospital, Izumo, JPN.

Glycogen storage disease type Ⅰa (GSDIa), also known as von Gierke disease, is a rare inherited metabolic disorder caused by defective glucose 6-phosphatase (G6Pase) activity. Although anemia, renal failure, and hepatic adenoma are the major clinical manifestations of GSDIa, there has been no report of refractory anemia in GSDIa patients on maintenance hemodialysis (HD) concomitant with multiple liver adenomas. Herein, we present a case of refractory anemia in a patient with GSDIa undergoing HD with multiple hepatic adenomas, successfully managed through aggressive treatment for renal anemia and intravenous iron therapy (IIT). Read More

View Article and Full-Text PDF

[Multidisciplinary regenerative treatment and mechanisms for rescuing a severe calciphylaxis patient with human amnion-derived mesenchymal stem cells].

Zhonghua Yi Xue Za Zhi 2022 Jul;102(28):2217-2221

State Key Laboratory of Reproductive Medicine, Center of Clinical Reproductive Medicine, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210036, China.

Calciphylaxis is a rare disease with severe pain and high-mortality due to cutaneous ischemic necrosis and infection that currently lacks proved effective therapies. The occurrence of calciphylaxis in end stage kidney disease (ESKD) patients is known as calcific uremic arteriolopathy (CUA), which is characterized histologically by dermal microvessel calcification, intimal fibroplasia and microthrombosis. Here we innovatively treated a severe CUA patient with human amnion-derived mesenchymal stem cells (hAMSCs). Read More

View Article and Full-Text PDF

A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment with Recombinant Erythropoietin While on Dialysis for End-Stage Renal Disease Who Recovered Following ABO-Incompatible Kidney Transplantation.

Am J Case Rep 2022 Jul 17;23:e935451. Epub 2022 Jul 17.

Division of Nephrology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

BACKGROUND Pure red cell aplasia (PRCA) is an uncommon cause of anemia in end-stage kidney disease (ESKD). It is attributed to recombinant human erythropoietin (rHuEPO) administration. Although immunosuppression is the mainstay therapy, its effectiveness varies from 30% to 70%. Read More

View Article and Full-Text PDF

[Anemia in Chronic Kidney Disease: The State of the Art].

Acta Med Port 2022 Jul 15. Epub 2022 Jul 15.

Anemia Working Group Portugal. Lisboa. Clínica de Insuficiência Cardíaca. Serviço de Medicina III. Hospital de S. Francisco Xavier. Centro Hospitalar de Lisboa Ocidental. Lisboa. NOVA Medical School. Faculdade de Ciências Médicas. Universidade Nova de Lisboa. Lisboa. Portugal.

The aging of the population has led to an increased prevalence of chronic diseases such as chronic kidney disease. Anemia is one of the most frequent complications of chronic kidney disease, with an impact not only on the quality of life but also on the patient's prognosis and associated costs. Knowledge in this therapeutic area has increased significantly: from the appearance of recombinant erythropoietin in 1989, through the use of increasing doses of parenteral iron and, more recently, to new molecules such as hypoxia-inducible factor inhibitors. Read More

View Article and Full-Text PDF

Soluble transferrin receptor can predict all-cause mortality regardless of anaemia and iron storage status.

Sci Rep 2022 Jul 13;12(1):11911. Epub 2022 Jul 13.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Despite interest in the clinical implications of soluble transferrin receptor (sTfR), previous studies on the association of sTfR with mortality in the general population are lacking. Therefore, we analysed the association between sTfR and all-cause mortality in the general United States adult population. We conducted a prospective cohort study using National Health and Nutrition Examination Survey data from 2003 to 2010. Read More

View Article and Full-Text PDF

Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease.

Adv Chronic Kidney Dis 2022 03;29(2):180-187.e1

Department of Medicine/Division of Nephrology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.

Anemia is a common medical problem among patients with cancer and chronic kidney disease (CKD). Although anemia in patients with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients. Read More

View Article and Full-Text PDF

Sickle Cell Disease and Kidney.

Adv Chronic Kidney Dis 2022 03;29(2):141-148.e1

Associate Professor of Hematology and Medical Oncology, Emory University School of Medicine, Director of Sickle Cell Research, Georgia Comprehensive Sickle Cell Center at Grady Health System, Winship Cancer Institute of Emory University, Atlanta, GA.

Sickle cell disease causes several kidney manifestations. They include defects in urine concentration, impaired handling of potassium and hydrogen ion, albuminuria, acute kidney injury, and chronic kidney disease to name a few. Glomerular hyperfiltration, tubular hyperfunctioning, endothelial damage from repeated sickling and vaso-occlusive episodes, and iron-induced proinflammatory changes in the glomerular mesangium and tubulointerstitium are some of the mechanisms of kidney damage. Read More

View Article and Full-Text PDF

Factors of Poor Prognosis Associated with Chronic Kidney Disease by Stage in Ambulatory Patients: A Cross-sectional Study.

Arch Med Res 2022 07 6;53(5):524-532. Epub 2022 Jul 6.

Servicio de Nefrología, Hospital General de México, Dr. Eduardo Liceaga, Ciudad de México, México. Electronic address:

Background: Mexico has a high prevalence of chronic kidney disease (CKD) but limited information about the early stages of CKD and their clusters of poor prognosis factors (PPF) such as hyperuricemia, electrolyte abnormalities or comorbidities.

Objective: To assess the prevalence of PPF by CKD stages in ambulatory patients.

Methods: A cross-sectional study with 1772 adult patients with CKD that attended the Nephrology Outpatient Clinic. Read More

View Article and Full-Text PDF

HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND.

Clin J Am Soc Nephrol 2022 08 5;17(8):1255-1258. Epub 2022 Jul 5.

William B. Schwartz MD Division of Nephrology, Tufts Medical Center, Boston, Massachusetts

View Article and Full-Text PDF

A nomogram to predict the in-hospital mortality of patients with congestive heart failure and chronic kidney disease.

ESC Heart Fail 2022 Jun 28. Epub 2022 Jun 28.

Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.

Aims: Patients with congestive heart failure (CHF) may also suffer from chronic kidney disease (CKD), and the two conditions may interact to increase the risk of death. The purpose of this study was to investigate the risk factors contributing to in-hospital mortality in patients with CHF and CKD and to develop a nomogram to predict the risk of in-hospital mortality.

Methods And Results: This retrospective study used data from the Marketplace for Medical Information in Intensive Care (MIMIC-IV, version 1. Read More

View Article and Full-Text PDF

Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait.

JAMA Intern Med 2022 Aug;182(8):796-804

Department of Psychiatry, Division of Human Genetics, Yale School of Medicine, New Haven, Connecticut.

Importance: Sickle cell trait (SCT), defined as the presence of 1 hemoglobin beta sickle allele (rs334-T) and 1 normal beta allele, is prevalent in millions of people in the US, particularly in individuals of African and Hispanic ancestry. However, the association of SCT with COVID-19 is unclear.

Objective: To assess the association of SCT with the prepandemic health conditions in participants of the Million Veteran Program (MVP) and to assess the severity and sequelae of COVID-19. Read More

View Article and Full-Text PDF

Early recovery status and outcomes after sepsis-associated acute kidney injury in critically ill patients.

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2022 May;47(5):535-545

Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha 410011.

Objectives: Acute kidney injury (AKI) is one of the common complications in critically ill septic patients, which is associated with increased risks of death, cardiovascular events, and chronic renal dysfunction. The duration of AKI and the renal function recovery status after AKI onset can affect the patient prognosis. Nevertheless, it remains controversial whether early recovery status after AKI is closely related to the prognosis in patients with sepsis-associated AKI (SA-AKI). Read More

View Article and Full-Text PDF

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.

Am J Hematol 2022 Sep 15;97(9):1178-1188. Epub 2022 Jul 15.

Section of Nephrology, Baylor College of Medicine, Houston, Texas, USA.

Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open-label, clinical trials in dialysis-dependent and non-dialysis-dependent patients with CKD and anemia, the hypoxia-inducible factor prolyl hydroxylase inhibitor, vadadustat, was noninferior to the erythropoiesis-stimulating agent, darbepoetin alfa, in increasing and maintaining target hemoglobin concentrations. In these trials, vadadustat increased the concentrations of serum EPO, the numbers of circulating erythrocytes, and the numbers of circulating reticulocytes. Read More

View Article and Full-Text PDF
September 2022

Renal Outcomes of Pregnancy-Related Acute Kidney Injury: a Single Centre Experience in India.

Maedica (Bucur) 2022 Mar;17(1):80-87

Department of Nephrology, AIIMS, New Delhi, India.

This study aimed to investigate the incidence, clinical characteristics, and outcomes of acute kidney injury (AKI) during pregnancy in Indian population. A prospective observational study was conducted in pregnant patients admitted to Pt. B. Read More

View Article and Full-Text PDF